Lexicon Pharmaceuticals (LXRX) Receivables - Net (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Receivables - Net for 17 consecutive years, with $11.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables - Net fell 75.17% year-over-year to $11.8 million; the TTM figure through Mar 2026 stood at $11.8 million (down 75.17% YoY), while the FY2025 annual figure was $2.4 million, down 31.36% from the prior year.
• Receivables - Net improved to $11.8 million in Q1 2026 per LXRX's latest filing, from $2.4 million in the prior quarter.
• Across five years, Receivables - Net topped out at $47.4 million in Q1 2025 and bottomed at $28000.0 in Q4 2022.
• Historically, Receivables - Net has averaged $4.7 million across 5 years, with a median of $1.5 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables - Net tumbled 78.62% — and 2023, when it jumped 3507.14%.
• Lexicon Pharmaceuticals' Receivables - Net stood at $28000.0 in 2022, then surged by 3507.14% to $1.0 million in 2023, then soared by 243.86% to $3.5 million in 2024, then tumbled by 31.36% to $2.4 million in 2025, then surged by 394.09% to $11.8 million in 2026.
• Business Quant data shows LXRX's Receivables - Net at $11.8 million in Q1 2026, $2.4 million in Q4 2025, and $2.3 million in Q3 2025.